MBC Advocate, following MBC breakthroughs
NYC
Joined October 2022
- Tweets5.1K
- Following1.1K
- Followers1.4K
- Likes15.7K
MBC News! FDA sets a June 2027 review goal for REVTORPYK. Celcuity said approval of the expansion would make REVTORPYK available as second-line therapy regardless of tumor PIK3CA status metastatic breast cancer. $CELC #SABCS26 stocktitan.net/news/CELC/cel…
1
402
Marengo 2 STARt-002: Most notably, confirmed complete responses were observed in both triple-negative and HR+/HER2-metastatic breast cancer, including a response continuing beyond one year in a patient with PD-L1-negative metastatic TNBC. #SITC26 #SABCS26 finance.yahoo.com/healthcare…
3
250
ATNM-400, investigational, first-in-class Actinium-225 antibody radioconjugate targeting HER3, an antigen implicated in tumor survival and treatment resistance. ATNM-400 combines the targeting specificity of a monoclonal antibody. $ATNM #SABCS26 stocktitan.net/news/ATNM/act…
Iksuda Therapeutics presents antibody drug conjugates (ADCs), preliminary data from its Phase 1 study for its HER2-directed ADC, IKS014, which is being assessed in patients with advanced or metastatic HER2+, HER2-low and HER2-mutated solid tumors. #SABCS26 morningstar.com/news/busines…
1
103
DYNASTY-Breast02 met its primary endpoint: PFS improved statistically significantly compared w/ chemo. Also a safety concern: More cases of interstitial lung disease were observed than in previous studies, including serious and fatal events. $BNTX #SABCS26 european-biotechnology.com/l…
1
131
Trastuzumab pamirtecan (BNT323/DB-1303) study of HER2-targeting ADC is being developed jointly with DualityBio and is undergoing Phase 3 testing hormone receptor-positive, HER2-low metastatic breast cancer. $BNTX #SABCS26 european-biotechnology.com/l…
Over 42,000 women die from metastatic breast cancer in the US yearly. Once tumors stop responding to SOC treatments targeted, hormonal therapies, chemo,ADC,immune checkpoint inhibitors,doctors run out of effective, data-backed options $BCTX $BCTXL #SABCS26 finance.yahoo.com/healthcare…
1
2
302
VIKTORIA-2 Enrollment is ongoing in the Phase 3 VIKTORIA-2 clinical trial that is evaluating gedatolisib combined w/ palbociclib and fulvestrant in the first-line setting for patients w/endocrine resistant HR+/HER2- metastatic breast cancer. $CELC #SABCS26 globenewswire.com/news-relea…
3
230
Olema will present: Palazestrant (OP-1250) in combination with atirmociclib, a phase 1b study, in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+, HER2-) advanced or metastatic breast cancer. $OLMA #SABCS26 stocktitan.net/news/OLMA/ole…
1
194
ARV-6723, Arvinas’ first immuno-oncology degrader.
Phase 1 trial will evaluate ARV-6723 as a monotherapy and in combination with pembrolizumab in patients with advanced solid tumors, metastatic breast cancer. $ARVN #SABCS26 ir.arvinas.com/news-releases…
2
211
Phase 1/2 clinical trial of ARV-6723, an investigational, oral PROteolysis TArgeting Chimera (PROTAC) designed to degrade hematopoietic progenitor kinase 1 (HPK1) in advanced solid tumors, metastatic breast cancer. $ARVN #SABCS26 ir.arvinas.com/news-releases…
Palazestrant (OP-1250) in combination with everolimus, a phase 1b/2 study, in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+, HER2-) advanced or metastatic breast cancer. $OLMA #SABCS26 firstwordpharma.com/story/83…
2
285
A phase 1 study of OP-3136, a novel oral selective KAT6A/B inhibitor, as monotherapy and in combination w/ endocrine therapy (ET) in estrogen receptor-positive (ER+), human epidermal growth factor-2-negative (HER2-) metastatic breast cancer. $OLMA #SABCS26 globenewswire.com/news-relea…
1
382
Avenzo Therapeutics will present preliminary results from its Phase 1 ORION-1 study of AVZO-023, a novel, selective CDK4 inhibitor, metastatic breast cancer, at the 2026 San Antonio Breast Cancer Symposium. #SABCS26
1
97
Country singer Nicole Taylor has passed away at just 35 from metastatic breast cancer. Diagnosed with early-stage breast cancer at 31, Nicole went into remission, but heartbreakingly, her cancer returned as Stage IV MBC.
She became a voice for young women living with MBC #SABCS26
1
7
415
Puma ALISCA - Breast1, a Phase II clinical trial of alisertib in combination with endocrine therapy for the treatment of patients with HER2-negative, HR-positive metastatic breast cancer. $PBYI #SABCS26 #JPM27 businesswire.com/news/home/2…
1
181
